Inhibikase Therapeutics, Inc.
General ticker "IKT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $158.8M (TTM average)
Inhibikase Therapeutics, Inc. follows the US Stock Market performance with the rate: 14.2%.
Estimated limits based on current volatility of 2.2%: low 1.69$, high 1.77$
Factors to consider:
- Total employees count: 14 as of 2023
- Top business risk factors: Going concern, Capital raising, Economic downturns and volatility, Pandemic risks, Litigation risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.05$, 2.81$]
- 2026-12-31 to 2027-12-31 estimated range: [0.99$, 2.64$]
Financial Metrics affecting the IKT estimates:
- Positive: with PPE of -3.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 1.17 > -0.60
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 95.42 > 64.29
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
Short-term IKT quotes
Long-term IKT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.26MM | $0.00MM | $0.00MM |
| Operating Expenses | $20.35MM | $28.59MM | $51.97MM |
| Operating Income | $-20.09MM | $-28.59MM | $-51.97MM |
| Non-Operating Income | $1.06MM | $1.07MM | $3.72MM |
| R&D Expense | $13.62MM | $17.21MM | $29.79MM |
| Income(Loss) | $-19.03MM | $-27.52MM | $-48.26MM |
| Net Income(Loss)* | $-19.03MM | $-27.52MM | $-48.26MM |
| Stockholders Equity | $10.98MM | $94.87MM | $172.90MM |
| Assets | $14.51MM | $98.60MM | $181.20MM |
| Operating Cash Flow | $-18.09MM | $-19.15MM | $-27.79MM |
| Capital expenditure | $0.01MM | $0.00MM | $0.01MM |
| Investing Cash Flow | $11.66MM | $-37.00MM | $2.05MM |
| Financing Cash Flow | $8.41MM | $103.48MM | $108.46MM |
| Earnings Per Share** | $-3.57 | $-0.40 | $-0.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.